LYEL lyell.com Net Assets per Single Share

Official company branding of Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma (LYEL) is building complex live-cell transportation systems, utilizing a network of cryogenic storage facilities to protect biomaterials and maintain high profitability. This price action, where the metric stands at 10.01, reflects the asset's dynamics. The company is attracting leading immunologists and bioinformaticians, investing in large-scale developments to significantly increase patient recovery rates.

LYEL Lyell Immunopharma Inc Net Asset Value per Share (07/04/2022 - 10/30/2026)

LYEL (lyell.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Price Lyell Immunopharma Inc|LYEL - Average Forecast Price
- market capitalization data:
Market Value Lyell Immunopharma, Inc.|LYEL - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Lyell Immunopharma|LYEL - Total Stockholders' Equity|Market Value to Book Value Ratio lyell.com|LYEL - Total Business Assets
- company total debt and liquidity indicators:
Total Debt to Capital Lyell Immunopharma|LYEL - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Lyell Immunopharma, Inc.|LYEL - Company Cumulative Debt|Debt to Book Capitalization Ratio Lyell Immunopharma, Inc.|LYEL - Company Long-Term Debt|Company Short-Term Debt Lyell Immunopharma|Quick Ratio lyell.com
- earnings and multiples data:
LYEL - Annual Net Income
Basic company analysis:LYEL - Lyell Immunopharma Inc
Manufactured products of Lyell Immunopharma, Inc.

For the biotech startup Lyell Immunopharma (LYEL), which faces high operating losses, monitoring net assets is critical, as a constant influx of capital directly impacts the size of shareholders' equity. This metric is calculated as the difference between all assets and liabilities divided by the number of shares, allowing the book value per common share to assess the real value of an investor's stake in the event of the company's liquidation.

Competitor analysis for Lyell Immunopharma

ImmunityBio Corp - Book Value per Share|Net Asset Value per Share Immunocore Corp|Janux Therapeutics (JANX) - Net Assets per Single Share|RCUS (arcusbio.com) - Net Assets per Single Share|Net Assets per Single Share Zymeworks|Net Asset Value per Share Tango Therapeutics Inc TNGX|Net Assets per Single Share Iovance (IOVA)|Immatics Biotechnologies - Equity per Share|Book Value per Share XNCR (Xencor, Inc.)|CMPX - Accounting Value per Share|REPL - Net Assets per Single Share|Net Asset Value per Share Innate Pharma SA|pyxisoncology.com (PYXS) - Net Assets per Single Share|CGEN (Compugen) - Net Assets per Single Share|Net Assets per Single Share IO Biotech, Inc.|Net Asset Value per Share sutrobio.com STRO|Book Value per Share INKT|werewolftx.com (HOWL) - Book Value of One Share|Immix Biopharma - Accounting Value per Share|ALX Oncology Holdings Inc. (ALXO) - Net Asset Value per Share|CUE: Accounting Value per Share|Accounting Value of a Share PDSB (PDS Biotechnology)|SONN: Book Value per Share|MAIA - Net Assets per Share|Net Assets per Single Share Liminatus Pharma Corp|Accounting Value per Share Lava Tx (LVTX)|Net Assets per Single Share NextCure, Inc. (NXTC)|Accounting Value per Share leaptx.com LPTX|Intensity Therapeutics, Inc. - Accounting Value per Share|Book Value per Share Sensei Biotherapeutics Inc SNSE|TOVX - Net Assets per Single Share|GRTS (Gritstone bio, Inc.) - Equity per Share|Kineta, Inc. (KA) - Net Assets per Single Share|Net Asset Value per Share neximmune.com (NEXI)|Accounting Value per Share TSBX|VCNX - Book Value of One Share|Accounting Value per Share HARP (Harpoon Tx)